This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second-line setting, an increasing number of studies this year have shown excellent efficacy in first-line therapy. The efficacy of bismuth as a second-line after sequential and concomitant therapy was particularly noteworthy. Antibiotic resistance was more intensely studied this year than for a long time, and definite trends are presented regarding an increase in resistance, including the fact that clarithromycin resistance in particular is now at a level where the continued use of clarithromycin triple therapy first-line as a mainstream treatment is not recommended. Another exciting trend to emerge this year is the utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult-to-treat groups.
| INTRODUCTION
The last year has been an extremely busy period for research publications on the treatment of Helicobacter pylori, driven by a series of articles in recent years suggesting that eradication rates with conventional therapies have fallen to unacceptable levels. The most significant paper of H. pylori treatment published this year was the fifth iteration of the Maastricht Consensus Report. 1 In this update, the importance of collating knowledge on local resistance patterns is emphasized, treatment regimens are extended to 14 days, standard proton-pump inhibitor (PPI)-clarithromycin-based triple therapy is limited to areas of low clarithromycin resistance, and rescue therapy options are explored further. In particular, quadruple therapies, bismuth containing, or otherwise are recommended as first-line when clarithromycin resistance exceeds 15% and as second-line in low resistance areas. When bismuth-based therapies fail in high resistance countries, levofloxacinbased triple therapy is recommended. Antimicrobial susceptibility testing (AST), standard or molecular is recommended after two treatment failures. The North American Toronto consensus also favored 14-day regimens. 2 This guideline recommended concomitant nonbismuth quadruple therapy and traditional bismuth quadruple therapy as firstline regimens and also restricting standard PPI triple therapy to areas with known low clarithromycin resistance. Recommended secondline therapies included bismuth quadruple therapy and levofloxacincontaining therapy. Rifabutin regimens were the preferred option for rescue patients who have failed to respond to at least 3 prior options.
A network meta-analysis of 30 systematic reviews ranked the esomeprazole to be the most effective PPI, followed by rabeprazole, while no difference was observed among the three old generations of PPI for the eradication of H. pylori. 3 A very large Swedish study looked at 157, 915 eradication episodes in 140, 391 individuals (1.5% of the Swedish population) and found good adherence to guidelines with 95.4% following the recommended regimen by national guidelines at the particular time. 4 Many studies have examined why eradication treatments fail.
The role of antibiotic resistance will be discussed later. A study from
Israel looked at the role of smoking and found the overall eradication failure rates to be 34.8% in current smokers and 32.8% in subjects who never smoked. 5 In a multivariate analysis, eradication failure was positively associated with current smoking, female gender, and low socioeconomic status, but after controlling for socio-demographic confounders, smoking was found to significantly increase the likelihood of unsuccessful first-line treatment for H. pylori infection. A
Chinese study looking at the role of compliance with therapy found that telephone follow-up did not increase the H. pylori eradication rate, but did improve compliance and satisfaction for the patients. 6 Other study with a view to resistance looked at whether previous antibiotic use could predict failure. In one study where a clarithromycinbased regimen was used, the eradication failure rate in patients with a history of macrolide use for >2 weeks was significantly higher than if the duration of use was <2 weeks (44.8% vs 29.3%). 7 Another study from Korea identified that the regions that suffered the most significant fall in eradication rates were those that had the highest rates of macrolide prescriptions. 8 
| TRIPLE THERAPY
In addition to the comparative studies described elsewhere, a number of studies looked at the role that standard triple therapy can play in H. pylori eradication treatment. A high-quality meta-analysis examined the efficacy of triple therapy with amoxicillin and metronidazole which showed that while overall they were less efficacious than clarithromycin-based regimens (70% vs 77%), efficacy was similar when drugs were administered for 14 days (80% vs 84%). 9 An Italian study looked at the effect of PPI dose and found eradication rates improved from 73.9% to 81.9% when double dose (40 mg esomeprazole) twice daily was used compared to standard (20 mg) dosing. 10 In terms of safety, a Japanese study of 322 patient showed a 15% incidence of diarrhea and 2% risk of skin rash.
11
A very interesting safety study looked at any association between H. pylori eradication therapy and the development of osteoporosis, a highly relevant topic in the context of recent data linking PPI use to osteoporosis. 12 An increase in the risk of developing osteoporosis was found to be higher in the early H. pylori treatment (within 1 year of diagnosis) cohort and also in the late H. pylori treatment cohort, compared with controls; however, when the follow-up period was Longer durations of therapy were associated with higher eradication rates, but with a higher risk of events that lead to discontinuation.
These findings, however, do little to counteract reservations that have been expressed in recent years that although sequential therapy has now been studied extensively and in many parts of the world, it has frequently been compared to 7-day standard triple or "legacy" therapy and that the comparator used does not reflect current best practice. showed such a result (84.6% vs 68%). 19 Two systematic reviews and meta-analyses of sequential therapy vs triple therapy found sequential treatment to be significantly more effective (82% vs 75% and 84.1% vs 75.1%, respectively). 20, 21 However, on subgroup analysis, both confirmed no benefit for sequential when longer triple therapy regimens were used. A study in which N-acetylcysteine (NAC) was used as an adjunct to sequential therapy showed overall very poor eradication rates but an improvement when NAC was used (58.0% vs 67.3%).
22
Concomitant therapy is similar to sequential in that it involves treatment with three antibiotics, but in contrast to sequential therapy, all three antibiotics are taken along with the PPI for the full duration of therapy. 23 A study from Spain this year showed it to be superior to 10-day triple therapy (85.9% vs 65.7%). 24 A meta-analysis of studies from regions of China found concomitant therapy to be superior to triple therapies of varying (but usually 7-day) regimens (91.2% vs 77.9%), but not significantly different from sequential therapy, albeit with better compliance for concomitant therapy. 25 Several studies this year compared sequential to concomitant therapy, with concomitant therapy showing superiority overall. An interesting paper from China reported an 86.1% eradication rate for concomitant therapy but also looked in depth at patients who failed eradication with this regimen. 26 They noted eradication was significantly higher in the group that received an esomeprazole-based regimen compared with the group that received an omeprazole-based regimen and that the omeprazolebased regimen was an independent risk factor for treatment failure as were CYP2C19 extensive metabolizer status, as well as clarithromycin and metronidazole resistance.
In a Korean study, where 10-and 14-day sequential and concomitant regimes were all used, all four regimens revealed eradication rates greater than 90% with the highest rate (98.5%) being for 14-day concomitant therapy. 27 A second Korean study compared triple therapy with sequential and concomitant regimens and found eradication rates of 62.6%, 70.6%, and 77.8%. 28 In a Greek prospective study, concomitant therapy outperformed sequential therapy by 89.1% vs 78.7%. 29 A further study from Saudi Arabia focussing on patients with perforated duodenal ulcers also suggested a trend toward improved eradication rates for concomitant rather than sequential therapy (81.8% vs 71.4%), but it did not reach statistical significance. 30 The inverse was seen in a study from Slovenia where 10-day sequential therapy (94.3% eradication) was significantly better than 7-day triple therapy (83.6%) in a clinical setting with low rates of resistance. 31 Concomitant therapy achieved eradication in 91.7% in this population, showing significant superiority over standard triple therapy only in the subgroup of patients with clarithromycin-resistant strains.
Hybrid therapy is an attempt to combine the principle of the induction phase of sequential therapy as a means of overcoming resistance with the benefits of four drugs, which is the characteristic of the concomitant therapy. It involves using PPI and amoxicillin for 14 days, while clarithromycin and metronidazole or equivalent are added for the final 7 days. 32 A prospective study this year of hybrid therapy as a first-line regimen was disappointing, revealing an eradication rate of 77%. 33 A systematic review published this year reported 77%-97% eradication with hybrid therapy and excellent compliance with low adverse event rates.
34
A head-to-head trial of hybrid vs concomitant therapy was carried out in Iran which demonstrated eradication rates of 87.3% for hybrid therapy compared to 80.9% for sequential. 35 One systematic review of 12 trials comparing sequential, concomitant and hybrid therapies showed no significant difference in eradication rates between the treatments with similarly high compliance rates and acceptable adverse event rates. 36 Another network meta-analysis carried out of Korean studies compared conventional triple therapy for 7 days, standard sequential therapy for 10 days, hybrid therapy for 10-14 days, and concomitant therapy for 10-14 days and reported eradication rates of 71.1%, 76.2%, 79.4% and 78.3%, respectively. in the second-line treatment. 38 Subgroup analysis in this study showed a decline in eradication rates after 2012, presumably due to rising resistance and surprisingly, better eradication rates when levofloxacin was given once daily rather than twice. A first-line study conducted in Iran this year found levofloxacin to be more effective than clarithromycin when given for two weeks as part of a triple therapy regimen (75% vs 51.7%). 39 In Portugal, where resistance rates to both levofloxacin and clarithromycin are high, higher eradication rates were observed for clarithromycin than for levofloxacin as part of first-line sequential regimens (90% vs 79%). 40 A separate randomized clinical trial examined whether levofloxacinbased second-line therapy was more effective if delivered as part of a 10-day triple regimen or sequential regimen and found that eradication rates were superior with sequential 90.2% vs 80.5%. 41 Another study investigated whether levofloxacin could be used with bismuth as part of a quadruple regimen when a non-bismuth-based quadruple regimen had failed to achieve eradication as first-line, and found a success rate of 73.5%. 42 As a third-line treatment, extended courses of levofloxacin-based therapies were examined in two separate studies from Korea which yielded divergent results. In one study, eradication rates were noted of 58.3% for 7-day therapy, 68.2% for 10-day therapy, and 93.3% for 14-day therapy. 43 In a separate study though no significant difference was noted between different treatment durations with the best rates seen for 7-day therapy at 80.6% compared to 64% for 10 days and 68.8% for 14 days. 44 A study of levofloxacin used in concomitant therapy compared to standard sequential therapy for patients with type 2 diabetes, often considered to be a difficult-to-treat group, reported 96.4% vs 81.4% eradication rates in favor of the levofloxacin arm. 45 Another group in Australia looked at difficult-to-treat patients with a median of 2 and up to 7 failed eradication attempts and reported 90% cure for levofloxacin-based triple therapy. 46 In Egypt, a novel quadruple combination of levofloxacin, nitazoxanide, doxycycline, and omeprazole prescribed for 14 days led to a successful eradication of H. pylori in 83% of patients who had previously failed first-line therapy. 47 Other fluoroquinolone antibiotics have also been tested with respect to H. pylori eradication this year. Sitafloxacin in particular was the subject of three studies in Japan. One of which looked at using sitafloxacin with four times daily rabeprazole in metronidazole-resistant patients and found eradication rates of 93.7% even though levofloxacin resistance was 42%. 48 Two other studies of sitafloxacin as a third-line agent were reported. As a triple regime with esomeprazole and amoxicillin, eradication rates for third-line were 83% in one study and 70.3% in a separate study which looked solely at patients harboring the gyrA mutation, which is associated with fluoroquinolone resistance. 49, 50 Another fluoroquinolone, gemifloxacin, was observed to have an eradication rate of 91.4% in 120 patients when used as part of a bismuth-based quadruple therapy. 51 A systematic review and meta-analysis of 16 studies on all quinolone-containing rescue therapies reported 10-day levofloxacin-amoxicillin-PPI triple therapy to achieve eradication rates of 80%. Regarding the moxifloxacin-amoxicillin-PPI triple therapy, efficacy was higher when administered for 14 days instead of 7 days (80% vs 63%). Only two levofloxacin-and bismuth-based quadruple regimens reported eradication rates greater than 90%
with similar safety in all treatments. 52 
| BISMUTH-BASED THERAPY
Bismuth is a commonly used agent in H. pylori eradication therapy, usually with metronidazole, tetracycline, and PPI and as part of a firstor second-line treatment. The utility of such regimens has been somewhat hampered by difficulties with the supply and availability of both bismuth itself and also tetracycline. A very high-quality study of over 5,000 patients which compared 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy observed the best eradication rates in the bismuth-based therapy arm (90.4%) compared to 85.9% for 10-day concomitant therapy and 83.7% for 14-day triple therapy, albeit with a higher frequency of adverse events 67%, 58% and 47%, respectively. 53 A separate Chinese study also showed superiority for bismuth-based therapy, this time compared to 10-day triple therapy (86.1% vs 58.4%). 54 A further study in Korea differed though with superior eradication rates being seen for 10-day sequential therapy than 14-day bismuth-based quadruple therapy. 55 In More novel variations of first-line bismuth-based therapy were also reported this year. A group from China reported two separate prospective studies from a region with high antibiotic resistance rates looking at bismuth-based quadruple therapy for 14 days with minocycline, amoxicillin, and in one case rabeprazole and the other esomeprazole. The rabeprazole group had eradication rates of 87.5% in first-line therapy and 82.9% for second-line. 58 The group receiving esomeprazole reported 85.5% eradication rates in first-line therapy and 82.8% for second-line. 59 A study from Croatia reported eradication rates of 80.64% for bismuth quadruple therapy with pantoprazole, metronidazole, and moxifloxacin. 60 Other studies examined combining levofloxacin and bismuth. One such study reported eradication rates of 86.7% for one week of quadruple therapy including bismuth and levofloxacin compared to 72.2%
for clarithromycin and bismuth and 75.56% for levofloxacin-based triple therapy in first-line patients. 61 A different Chinese group observed similar eradication rates for a bismuth-based quadruple therapy whether amoxicillin or cefuroxime was used (83.5% vs 81.0%).
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Some reports focussed solely on the role of bismuth as secondline therapy, a high-quality US study found the use of metronidazole and amoxicillin provided similar eradication rates (88.5% vs 87.7%) to classical bismuth quadruple therapy but with superior safety and compliance. 63 In France, a study of Pylera ® as second-line therapy showed similar high efficacy to that reported in Italy with 83% achieving eradication. 64 In Korea, an interesting study noted that although eradication rates of 73.9% were observed, a multivariate analysis showed that diabetes mellitus was strongly associated with H. pylori eradication therapy failure. 65 
| DUAL THERAPY
Enhanced dual therapy may also be a useful option for H. pylori eradication and has been studied more in recent years. Two Asian studies addressed the question this year. As a first-line option, a 
| RIFABUTIN
Rifabutin can be a useful option for H. pylori eradication treatment although its use is limited by potentially severe adverse events such as myelotoxicity and concerns regarding promoting the spread of multidrug-resistant tuberculosis. Nonetheless, in difficult scenarios, it is of some benefit. A study from Japan found in third-or fourth-line therapy that 83.3% achieved eradication after 10 days of rifabutinbased triple therapy and 94.1% after 14 days. 68 A separate pilot study from Italy reported 96.6% for a 10-day bismuth-based quadruple regimen containing rifabutin compared to 66.7 in the 10-day rifabutinbased triple therapy arm. 69 Less impressive results were found in a 12-patient cohort in Korea in whom only 50% achieved eradication although this study was significantly skewed by the fact that some patients received therapy for 7 days and others 14 days. 70 In a large study from Italy looking at 254 patients harboring triple-resistant (clarithromycin, metronidazole, levofloxacin) strains 82.9% of the patients were cured with a rifabutin-based triple therapy. 71 
| ANTIMICROBIAL RESISTANCE
A significant and welcome increase was noted over the last year in the number of studies addressing the important topic of antimicrobial resistance in H. pylori infection. These are summarized in Table 1 . A key message emerging is the relentless rise in antibiotic resistance, especially to clarithromycin and levofloxacin. Although the pace of this increase appears to be variable, the trend is a clear one. In many regions of western Europe such as Ireland, Germany, and France where clarithromycin resistance had previously been low, recent studies have
shown an increase in rates above the level of 20% (now 15%) where it has long been considered that clarithromycin-based triple therapy ought to be abandoned as a primary treatment strategy. 76, 81, 84 In contrast, resistance in Austria remains low. 86 The correlation between in vivo and in vitro resistance in H. pylori has long been questioned. An interesting paper from a French group this year showed a good correlation between the clarithromycin resistance detected by phenotypic methods and the associated mutations for clarithromycin resistance and also that no patients receiving Pylera developed resistance to tetracycline. 84 A study from Poland looked at tailoring initial triple therapy based on AST to amoxicillin, clarithromycin, levofloxacin, and metronidazole and found that, when such a strategy was employed, eradication rates were significantly better (95.5% vs 86.6%). 77 This strategy has previously been used predominantly for third-line or "rescue" therapies. A meta-analysis on this topic was conducted this year which concluded that cure rates, using susceptibility-guided treatment, were 72% and that the evidence in favor of such a rescue therapy is currently insufficient to recommend its use. 93 
| PROBIOTICS
Several articles this year described the effect of probiotic treatment on H. pylori eradication therapy. Regarding probiotics, there were a few original studies that reported interesting results as well as three meta-analyses. A study of 159 patients in Turkey treated with sequential therapy revealed that 86.8% of patients in the group receiving probiotics alongside the sequential therapy achieved eradication compared to 70.8% without. 94 When used with quadruple bismuthbased therapy, the provision of probiotic and prebiotic supplementation also led to greater eradication rates (92.1% vs 63.2%). 95 The proposed benefits of probiotic supplementation are thought by some to lie in altering the microbiome in such a manner as to limit diarrhea side effects, thus improving tolerance, compliance and eradication rates. One study this year analyzed the microbiome of patients receiving probiotics compared to those receiving just eradication therapy alone. 96 The overall alterations in microbiota, as revealed by metagenome sequencing, were similar, but the proportional shift in functional gene families was greater in the antibiotic group than in the probiotic only group leading to functional alterations of gut microbiota which may link to the reduction in intestinal irritation and maintenance of bacterial diversity observed following probiotic supplementation with antibiotic therapy.
One high-quality meta-analysis probed into the individual strains used in the relevant studies and showed that four multistrain pro- eight-strain mixture) had significant efficacy for all three outcomes.
97
A separate meta-analysis which emphasized the heterogeneity of the 13 studies identified that pooled relative risk of eradication was significantly higher in the probiotic supplementation group than in the control group and the incidence of total antibiotic-related side effects was lower in the probiotic supplementation group than in the control group. 98 A further meta-analysis of 30 randomized clinical trials with significant heterogeneity found eradication rates improved by 12.2% when probiotics were used in supplementation. 99 
| VONOPRAZAN
Vonoprazan is a first-in-class orally bioavailable potassiumcompetitive acid blocker (P-CAB) which has been developed for the treatment and prevention of acid-related diseases. It inhibits the H+, K+-ATPase-mediated gastric acid secretion in a reversible and potassium-competitive manner and is thought to possess more potent inhibitory effects than PPI offering a potential benefit for H. pylori eradication. A raft of literature has emerged from Japan in the last year where this agent is approved for use, all of which have found superiority for vonoprazan over PPI in triple therapy formats. [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] This is summarized in Table 2 . It is noteworthy, however, that vonoprazan has been tested in triple therapies only and not in other regimens such as quadruple therapy, sequential therapy, or with bismuth.
One high impact retrospective study of more than 600 patients showed eradication rates of 89.1% for vonoprazan when used as a triple therapy with amoxicillin and clarithromycin compared to 70.9% when PPI was used with no significant difference in the incidence of adverse events. 101 A separate prospective study on a similar number of patients which included 50 undergoing second-line therapy yielded a first-line 
| CONCLUSION
There have been many and varied number of studies pertaining to treatments up to 14 days. 112 Bismuth based therapies are performing very well across numerous regions and the more novel pairings of it either as part of a "single triple" capsule or with other antibiotics may well enable clinicians to overcome some of the issues around tetracycline supply that have hampered the widespread adoption of bismuth based therapy. Levofloxacin and rifabutin remain useful alternatives, especially in rescue therapy settings. Excellent results for studies using vonoprazan has been a very noteworthy development this year but this will need to be robustly examined in regions outside Japan and also compared with regimens other than standard triple therapy.
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